

S2 | A partial list of genes that are silenced by aberrant DNA hypermethylation in cancer.

Gene function	Gene name	Cancer type	References
Cell-cycle regulation	<i>RBI</i>	Retinoblastoma	1
	<i>CDKN2A</i> (<i>INK4A</i> transcript)	Colon, lung, many others	2
	<i>CDKN2A</i> (<i>ARF</i> transcript)	Colon	3
Tumour-cell invasion	<i>CDH1</i>	Breast, gastric, thyroid, leukemia, liver	4
	<i>CDH13</i>	Lung, ovarian, pancreatic	5
	<i>TIMP3</i>	Brain, kidney	6
	<i>VHL</i>	Renal cell	7
DNA repair / detoxification	<i>MLH1</i>	Colon, endometrial, gastric	8
	<i>MGMT</i>	Brain, colon, lung, breast	9
	<i>BRCA1</i>	Breast, ovarian	10
	<i>GSTP1</i>	Prostate, liver, colon, breast, kidney	11
Chromatin remodelling	<i>SMARCA3</i>	Colon, gastric	12
Cell signalling	<i>RASSF1A</i>	Lung, liver, brain	13
	<i>SOCS1</i>	Liver, colon, multiple myeloma	14
Transcription	<i>ESR1</i>	Colon, breast (oestrogen-receptor negative), lung, leukemia	15
Apoptosis	<i>DAPK1</i>	Lymphoma	16

CDKN2A, cyclin-dependent kinase inhibitor 2A; *CDH1*, cadherin 1 (E-cadherin); *CDH13*, cadherin 13 (H-cadherin); *ESR1*, oestrogen receptor 1 (also known as *ER*); *MLH1*, mutL homolog 1; *RBI*, retinoblastoma 1; *SMARCA3*, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 3 (also known as *HLTF*); *TIMP3*, tissue inhibitor of metalloproteinase 3; *VHL*, von Hippel-Lindau tumor suppressor;

References

1. Stirzaker, C. et al. Extensive DNA methylation spanning the *Rb* promoter in retinoblastoma tumors. *Cancer Res.* **57**, 2229-2237 (1997).

2. Herman, J.G. et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res.* **55**, 4525-4530 (1995).
3. Robertson, K.D. & Jones, P.A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. *Mol. Cell. Biol.* **18**, 6457-6473 (1998).
4. Graff, J.R. et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. *Cancer Res.* **55**, 5195-5199 (1995).
5. Toyooka, K.O. et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. *Cancer Res.* **61**, 4556-4560 (2001).
6. Bachman, K.E. et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. *Cancer Res.* **59**, 798-802 (1999).
7. Herman, J.G. et al. Silencing of the *VHL* tumor-suppressor gene by DNA methylation in renal carcinoma. *Proc. Natl. Acad. Sci. USA* **91**, 9700-9704 (1994).
8. Kane, M.F. et al. Methylation of the *hMLH1* promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. *Cancer Res.* **57**, 808-811 (1997).
9. Qian, X.C. & Brent, T.P. Methylation hot spots in the 5' flanking region denote silencing of the O⁶-methylguanine-DNA methyltransferase gene. *Cancer Res.* **57**, 3672-3677 (1997).
10. Dobrovic, A. & Simpfendorfer, D. Methylation of the *BRCA1* gene in sporadic breast cancer. *Cancer Res.* **57**, 3347-3350 (1997).
11. Lee, W.-H. et al. Cytidine methylation of regulatory sequences near the π -class glutathione *S*-transferase gene accompanies human prostatic carcinogenesis. *Proc. Natl. Acad. Sci. USA* **91**, 11733-11737 (1994).
12. Moinova, H.R. et al. *HTLF* gene silencing in human colon cancer. *Proc. Natl. Acad. Sci. USA* **99**, 4562-4567 (2002).
13. Dammann, R. et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. *Nature Genet.* **25**, 315-319 (2000).
14. Yoshikawa, H. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. *Nature Genet.* **28**, 29-35 (2001).
15. Issa, J.-P. et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nature Genet.* **7**, 536-540 (1994).
16. Katzenellenbogen, R.A., Baylin, S.B. & Herman, J.G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. *Blood* **93**, 4347-4353 (1999).